Plandai Biotechnology, Inc. Announces Appointment of Additional Renowned Scientist to Its Scientific Board
February 29 2012 - 9:30AM
Marketwired
Plandaí Biotechnology, Inc. (OTCBB: PLPL) Chief Executive Officer,
Roger Duffield, announced today that Dr. Ming Hu, Professor of
Pharmaceutics at the University of Houston, has accepted a position
on the company's scientific board. Dr. Hu has published more than
76 peer reviewed journal articles and 13 review articles and book
chapters, and is widely considered a leading expert in the field of
drug metabolism and natural dietary chemicals. His book titled
"Oral Bioavailability" was published in 2011 by Wiley and Sons.
With Dr. Christina Nance from the Baylor School of Medicine, Dr.
Hu is the co-investigator in a US government-funded clinical trial
NCT01433289, to determine the safety, dosing and antiviral effects
of epigallocatechin gallate (EGCG) in capsule form with HIV-1
infected, clinically stable individuals that are not on concomitant
antiretroviral (ARV) Therapy.
Dr. Hu has extensively studied the absorption of chemicals in
the upper intestines, as a process for effectively delivering
flavonoid nutrients, such as those found in green tea extract; and
has proposed a method of understanding the coupling between
conjugating enzyme and efflux transporters. Conjugating enzymes are
traditionally recognized as one of the major biological barriers to
the entry of xenobiotics (drugs) into systemic circulation. Drugs
that undergo extensive conjugation generally have poor
bioavailability properties. Dr. Hu has also pioneered the concept
of using lipozyme as a powerful, fat-digesting complex that aids
digestion and enhances absorption of nutrients.
Dr. Hu's extensive published research extends to improving the
bioavailability of natural, organic compounds with cancer fighting
properties including both phenolics and ginseng; purifying
anticancer ingredients of herbal materials and decreasing the
bioavailability of dietary carcinogens.
Roger Duffield, Chief Executive Officer of Plandaí, commented,
"In his role on Plandaí's scientific board, Dr. Hu will be able to
apply his specific expertise to the development of highly
effective, bioavailable products that are easily metabolized in the
body. Having a researcher of his caliber and background on our team
is a huge benefit as we continue building Plandaí into a leader in
the field of biotechnology."
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc., through its recent acquisition of
Global Energy Solutions, Ltd. and its subsidiaries, focuses on the
farming of whole fruits, vegetables and live plant material and the
production of proprietary functional foods and botanical extracts
for the health and wellness industry. Its principle holdings
consist of land, farms and infrastructure in South Africa.
Safe Harbor Statement
The information provided may contain forward-looking statements
and involve risks and uncertainties. Results, events and
performances could vary from those contemplated. These statements
involve risks and uncertainties which may cause actual results,
expressed or implied, to differ from predicted outcomes. Risks and
uncertainties include product demand, market competition, and
Plandaí's ability to meet current or future plans. Investors should
study and understand all risks before making an investment
decision. Readers are recommended not to place undue reliance on
forward-looking statements or information. Plandaí is not obliged
to publicly release revisions to any forward-looking statement, to
reflect events or circumstances afterward, or to disclose
unanticipated occurrences, except as required under applicable
laws.
Contact: Roger Duffield Tel: (425) 466-0212 Email: Email
Contact
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Apr 2023 to Apr 2024